Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Product Recalls in 2013 Categorized by Problem Area

This article was originally published in The Gold Sheet

Executive Summary

This comprehensive table provides key facts at a glance for every one of the 1,276 drug recalls FDA reported last year, grouped into seven main problem areas. For each recall, it says what product was recalled and how much of it was recalled, what company manufactured it and recalled it, how seriously FDA rated the health threat the recalled product posed, and what reason the company gave for recalling the product.

You may also be interested in...



Herbal Sleep Aid With Rx 'Reformulation' Gives FDA A Nightmare

FDA inspects Belmora's website and product labeling in March and issues a warning letter that firm’s Elavil OTC Sleep Aid is an unapproved new drug with inadequate directions for its intended use.

Rx 'Reformulation' In Herbal Sleep Aid Gives FDA A Nightmare

FDA inspects Belmora's website and product labeling in March and issues a warning letter that firm’s Elavil OTC Sleep Aid is an unapproved new drug with inadequate directions for its intended use.

Rx 'Reformulation' In Herbal Sleep Aid Gives FDA A Nightmare

FDA inspects Belmora's website and product labeling in March and issues a warning letter that firm’s Elavil OTC Sleep Aid is an unapproved new drug with inadequate directions for its intended use.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS000838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel